INHIBITING GLYCO-IMMUNE CHECKPOINTS
Targeting the Siglec-Sialoglycan Axis to Treat Cancer

INHIBITING GLYCO-IMMUNE CHECKPOINTS

From discovery to breakthrough

Targeting glycan-sensing checkpoints to unleash both innate and adaptive immune response to cancer

Our path to patient impact

Developing novel, first-in-class medicines to transform the treatment of cancer

Our team

We are driven to advance a completely new modality for cancer